Search results for "relap"

showing 10 items of 217 documents

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Thera…

2022

Simple Summary We present the long-term results of patients receiving allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory mantle cell lymphoma (R/R MCL) in the last 25 years in Spain. We conclude that allo-SCT may be a curative option in R/R MCL with a low cumulative incidence (CI) of relapse, although non-relapse mortality (NRM) is still high, which is mainly secondary to acute graft-versus-host disease (aGVHD). Results are better for fit patients, using HLA-identical (related or unrelated) or haploidentical related donors and without previous ASCT. However, the arrival of new highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegat…

CAR-T cell therapyCancer ResearchLimfomesMantle cell lymphomaAcute graft-versus-host diseaseTransplantation of organstarget therapyacute graft-versus-host diseasemantle cell lymphomaTarget therapyTrasplantament d'òrgansgraft-versus-lymphoma effectnon-relapse mortalityOncologyNon-relapse mortalityimmune system diseaseshemic and lymphatic diseasesallogeneic stem-cell transplantationmantle cell lymphoma; allogeneic stem-cell transplantation; non-relapse mortality; acute graft-versus-host disease; graft-versus-lymphoma effect; target therapy; CAR-T cell therapyLymphomasAllogeneic stem-cell transplantationCàncerGraft-versus-lymphoma effect
researchProduct

Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.

2013

Laquinimod is an orally administered compound that is under investigation in relapsing-remitting multiple sclerosis. To understand the mechanism by which laquinimod exerts its clinical effects, we have performed human and murine studies assessing its immunomodulatory properties. In experimental autoimmune encephalomyelitis, the therapeutic administration of laquinimod beginning during the recovery of SJL mice, prevented further relapses as expected and strongly reduced infiltration of CD4+ and CD8+ T cells in the central nervous system. We hypothesized that this beneficial effect was mediated by dendritic cells, since we and others found a modulation of different dendritic cell subsets unde…

CD4-Positive T-LymphocytesChemokineEncephalomyelitis Autoimmune ExperimentalT cellQuinoloneschemistry.chemical_compoundMiceMultiple Sclerosis Relapsing-RemittingmedicineAnimalsHumansbiologyMonocyteExperimental autoimmune encephalomyelitisNF-kappa BDendritic cellDendritic Cellsmedicine.diseaseMice Inbred C57BLmedicine.anatomical_structurechemistryImmunologybiology.proteinCytokine secretionFemaleNeurology (clinical)LaquinimodCD8Brain : a journal of neurology
researchProduct

Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study

2022

AbstractSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination plays a crucial role as pivotal strategy to curb the coronavirus disease-19 (COVID-19) pandemic. The present study described the clinical status of patients affected by idiopathic inflammatory myopathies (IIM) after COVID-19 vaccination to assess the number of relapses. We included all patients affected by IIM and followed by Myositis Clinic, Rheumatology and Respiratory Diseases Units, Siena University Hospital, Bari University Hospital, Policlinico Umberto I, Sapienza University, Rome, and Policlinico Paolo Giaccone, Palermo. They underwent a telephone survey. A total of 119 IIM patients (median, IQR 58 (47–6…

COVID-19 VaccinesMyositisCOVID-19 vaccinationSARS-CoV-2VaccinationCOVID-19Relapses.RecurrenceEmergency MedicineInternal MedicineHumansCOVID-19 vaccination; Idiopathic inflammatory myopathies; RelapsesIdiopathic inflammatory myopathiesIdiopathic inflammatory myopathieRelapses
researchProduct

Recent Advances in the Treatment of Patients with Multiple Myeloma

2020

Simple Summary The evolving data from trials assessing novel combinations as a part of the frontline and relapse treatment in transplant and non-transplant candidates have markedly improved the anti-myeloma efficacy of the different therapeutic regimens and improved patients’ prognosis. Current treatment objectives are focused to further improve the rate of complete remission, time to progression, progression-free survival and overall survival without increasing toxicity. Besides, different strategies are being developed in the elderly population as this group of patients requires a closer monitoring with individualized, dose-modified regimens to improve tolerability while maintaining their…

Cancer Researchmedicine.medical_specialtyautologous stem cell transplantationmedicine.medical_treatmentHematopoietic stem cell transplantationDiseaseNewly diagnosedReviewlcsh:RC254-282maintenance03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationmedicinecar-t cellsIntensive care medicineMultiple myelomanovel drugsbusiness.industryrelapsed refractory multiple myelomaearly relapseAdvanced stageImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensClinical trialmultiple myelomalate relapseOncology030220 oncology & carcinogenesisimmunotherapybusinessconsolidation030215 immunologyCancers
researchProduct

Acetaldehyde as a drug of abuse: insight into AM281 administration on operant-conflict paradigm in rats

2013

Increasing evidence focuses on acetaldehyde (ACD) as the mediator of the rewarding and motivational properties of ethanol. Indeed, ACD stimulates dopamine release in the nucleus accumbens and it is self-administered under different conditions. Besides the dopaminergic transmission, the endocannabinoid system has been reported to play an important role in ethanol central effects, modulating primary alcohol rewarding effect, drug-seeking and relapse behaviour. Drug motivational properties are highlighted in operant paradigms which include response-contingent punishment, a behavioural equivalent of compulsive drug use despite adverse consequences. The aim of this study was thus to characterize…

Cannabinoid receptorPunishment (psychology)media_common.quotation_subjectCognitive NeuroscienceNucleus accumbenslcsh:RC321-571Behavioral NeuroscienceDopamineCB1 AntagonistmedicineOriginal Research ArticleGeiller-Seifter procedurelcsh:Neurosciences. Biological psychiatry. Neuropsychiatrymedia_commonrelapseAddictionDopaminergicExtinction (psychology)Endocannabinoid systemGeiller–Seifter procedureNeuropsychology and Physiological PsychologyCB1 receptor blockade/antagonismSettore BIO/14 - FarmacologiaAcetaldehyde Lever pressing relapse Geiller-Seifter procedure CB1 receptor blockade/antagonismPsychologyNeurosciencepsychological phenomena and processesmedicine.drugNeuroscienceacetaldehydelever pressingFrontiers in Behavioral Neuroscience
researchProduct

Multiple sclerosis patient-derived CSF induces transcriptional changes in proliferating oligodendrocyte progenitors.

2014

Background: Cerebrospinal fluid (CSF) is in contact with brain parenchyma and ventricles, and its composition might influence the cellular physiology of oligodendrocyte progenitor cells (OPCs) thereby contributing to multiple sclerosis (MS) disease pathogenesis. Objective: To identify the transcriptional changes that distinguish the transcriptional response induced in proliferating rat OPCs upon exposure to CSF from primary progressive multiple sclerosis (PPMS) or relapsing remitting multiple sclerosis (RRMS) patients and other neurological controls. Methods: We performed gene microarray analysis of OPCs exposed to CSF from neurological controls, or definitive RRMS or PPMS disease course. R…

Cell physiologyAdultPathologymedicine.medical_specialtyTranscription GeneticGalectin 3GalectinsImmunocytochemistryBiologyArticleCerebrospinal fluidMultiple Sclerosis Relapsing-RemittingNeural Stem CellsmedicineAnimalsHumansProgenitor cellCells CulturedCell ProliferationCerebrospinal FluidMultiple sclerosisBrainHuman brainBlood ProteinsMultiple Sclerosis Chronic Progressivemedicine.diseaseMicroarray AnalysisNeural stem cellOligodendrocyteRatsUp-RegulationOligodendrogliamedicine.anatomical_structureNeurologyNeurology (clinical)Multiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients

2020

Background: Progressive multifocal leukoencephalopathy (PML) can in rare cases occur in natalizumab-treated patients with high serum anti-JCPyV antibodies, hypothetically due to excessive blockade of immune cell migration. Objective: Immune cell recruitment to the central nervous system (CNS) was assessed in relapsing-remitting multiple sclerosis (RRMS) patients stratified by low versus high anti-JCPyV antibody titers as indicator for PML risk. Methods: Cerebrospinal fluid (CSF) cell counts of 145 RRMS patients were quantified by flow cytometry. Generalized linear models were employed to assess influence of age, sex, disease duration, Expanded Disability Status Scale (EDSS), clinical/radiol…

CellCell Countprogressive multifocal leukoencephalopathycerebrospinal fluidMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineNatalizumabCerebrospinal fluidmedicineHumansJCV index030304 developmental biology0303 health sciencesbiologybusiness.industryNatalizumabMultiple sclerosisProgressive multifocal leukoencephalopathyLeukoencephalopathy Progressive MultifocalJCPyVmedicine.diseaseJC VirusCSF cell countstissue-resident memory cellsBlockadeclinical activityTitermedicine.anatomical_structureNeurologyImmunologybiology.proteinNeurology (clinical)AntibodybusinessOriginal Research Papers030217 neurology & neurosurgerymedicine.drugMultiple Sclerosis Journal
researchProduct

Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable t…

2023

Background Sleep disorders are common in patients with multiple sclerosis and have a bidirectional interplay with fatigue and depression. Objective To evaluate the effect of treatment with oral dimethyl fumarate on the quality of sleep in relapsing-remitting multiple sclerosis. Methods This was a multicentre observational study with 223 relapsing-remitting multiple sclerosis subjects starting treatment with dimethyl fumarate ( n=177) or beta interferon ( n=46). All patients underwent subjective (Pittsburgh Sleep Quality Index) and objective (wearable tracker) measurements of quality of sleep. Fatigue, depression, and quality of life were also investigated and physical activity was monitored…

Cellular and Molecular Neurosciencerelapsing remitting multiple sclerosisSettore MED/26 - NeurologiaNeurology (clinical)sleepDimethyl fumaratewearable trackerMultiple Sclerosis Journal - Experimental, Translational and Clinical
researchProduct

Long-term stability of surgical-orthodontic correction of class III malocclusions with long-face syndrome

2011

Objectives: In the first place, to evaluate skeletal changes of the maxilla and mandible induced by surgical-orthodontic correction of malocclusions class III with long-face syndrome and secondly, to analyze the stability of these skeletal changes in the long term (more than 6 years). Design of Study: A retrospective, unicentric and longitudinal study of 19 patients who had undergone surgical and orthodontic therapy for class III skeletal malocclusion with long-face syndrome was undertaken. A cephalometric analysis based on 8 angle measurements, and statistical analyses at three different points in time (before orthodontic treatment, after orthognathic surgery and after a retention period o…

Cephalometric analysisAdultMaleLongitudinal studyClass IIITime FactorsAdolescentCephalometrymedicine.medical_treatmentOrthognathic surgeryDentistryOrthodontics CorrectiveYoung Adultstomatognathic systemmedicineHumansLongitudinal StudiesRelapseGeneral DentistryOrthognathic surgeryRetrospective StudiesOrthodonticsLong face syndromebusiness.industryMandibleSyndromemedicine.disease:CIENCIAS MÉDICAS [UNESCO]Malocclusion Angle Class IIILong faceOtorhinolaryngologyJawMaxillaCephalometryFaceUNESCO::CIENCIAS MÉDICASSurgeryFemaleResearch-ArticleMalocclusionmedicine.symptomOral SurgerybusinessStabilityFollow-Up StudiesLong term results
researchProduct

Cognitive impairment in relapsing-remitting multiple sclerosis can be predicted by imaging performed several years earlier.

2007

Cognitive deficits in multiple sclerosis (MS) are common and correlate with contemporary MRI brain abnormalities, particularly atrophy, but the ability of imaging early in the disease to predict later cognitive impairment remains to be determined. Thirty relapsing—remitting MS patients recruited within three years of the onset of the disease, and in whom MRI had been performed at baseline and a year later, were assessed neuropsychologically five years later. Imaging parameters accounting for significant variance in cognitive performance were identified using multiple regressions, once confounding variables were controlled. Patients performed significantly worse than expected on tests of at…

Cognitive deficits in multiple sclerosisAdultMalePediatricsmedicine.medical_specialtyDevelopmental psychologyCentral nervous system diseaseDisability EvaluationAtrophyDegenerative diseaseMultiple Sclerosis Relapsing-Remittingrelapsing-remitting multiple sclerosiPredictive Value of TestsmedicineHumansMultiple sclerosiCognitive impairmentMultiple sclerosisCognitive disorderCognitionMiddle Agedmedicine.diseaseMagnetic Resonance ImagingEarly DiagnosisNeurologyRelapsing remittingLinear ModelsFemaleNeurology (clinical)AtrophyPsychologyCognition DisordersFollow-Up StudiesMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct